← Back to Search

Behavioural Intervention

Exercise Training for Kidney Cancer

N/A
Waitlist Available
Led By Yasser Ged, MD
Research Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients being treated with standard of Programmed cell death protein 1 (anti-PD-1) or anti-PD-L1 immune-checkpoint inhibitor-containing standard of care regimen including patients who are about to start treatment or have been on treatment for a maximum of 4 weeks prior to signing consent
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 with a life expectancy ≥ six months
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial is testing the effects of personalized exercises on quality of life and inflammation.

Eligible Conditions
  • Kidney Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You are currently receiving a specific type of immunotherapy treatment or are about to start it within four weeks.
Select...
You are able to do daily activities with little or no help, and are expected to live for at least six more months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants who adhere to the exercise intervention
Secondary outcome measures
Change in HRQoL as measured by FACT-G Questionnaire
Percentage of patients screened compared to patients enrolled
Percentage of patients who remained in the study and didn't drop off the study after enrollment
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Supportive CareExperimental Treatment1 Intervention
Patients with metastatic renal cell carcinoma (RCC) who are receiving immune-checkpoint inhibitor therapy

Find a Location

Who is running the clinical trial?

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
557 Previous Clinical Trials
32,898 Total Patients Enrolled
Yasser Ged, MDPrincipal InvestigatorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
1 Previous Clinical Trials
37 Total Patients Enrolled

Media Library

Combined Aerobic and Resistance Exercise Training (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05103722 — N/A
Kidney Cancer Research Study Groups: Supportive Care
Kidney Cancer Clinical Trial 2023: Combined Aerobic and Resistance Exercise Training Highlights & Side Effects. Trial Name: NCT05103722 — N/A
Combined Aerobic and Resistance Exercise Training (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05103722 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this investigation include participants of advanced age?

"To be eligible for this medical trial, applicants must be between 18 and 99 years old. The database reveals 83 clinical trials specifically designed to accommodate people under the age of majority while 2564 are available to those aged over 65."

Answered by AI

Are participants being accepted for this research endeavor at present?

"Affirmative, the clinicaltrials.gov website indicates that this medical study is still open for recruitment. It was initially posted on February 17th 2022 and last updated on March 28th 2022; 16 patients are required at one hospital site."

Answered by AI

Could I be considered a participant in this research?

"This scientific experiment is recruiting sixteen individuals with carcinoma who are between eighteen and ninety-nine years of age. To be eligible for enrollment, people must meet a set of criteria including: having metastatic measurable disease, being treated by the standard Programmed cell death protein 1 (anti-PD-1) or anti-PD-L1 immune checkpoint inhibitor containing regimen, a histologically confirmed diagnosis of RCC, Eastern Cooperative Oncology Group performance status 0 to 2 and life expectancy exceeding six months, physical ability to participate in an exercise program evaluated by Physical medicine and rehabilitation physicians at Johns Hopkins University Hospital Medical Center; Absolute Neutroph"

Answered by AI

How many participants are taking part in this research study?

"Affirmative. The clinicaltrial.gov website reports that this study is actively recruiting participants; it was initially published on February 17th 2022 and subsequently modified on March 28th 2022. Additionally, 16 individuals must be enrolled at one medical site for the trial to commence."

Answered by AI
~1 spots leftby Apr 2025